Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects

Published:2017-02-27 Issue:9 Volume:45 Page:1213-1224
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Wong G. L.-H.¹²³^ORCID,Tse Y.-K.¹²,Yip T. C.-F.⁴,Chan H. L.-Y.¹²³,Tsoi K. K.-F.⁵,Wong V. W.-S.¹²³^ORCID

Affiliation:

1. Institute of Digestive Disease; The Chinese University of Hong Kong; Hong Kong China

2. Department of Medicine and Therapeutics; The Chinese University of Hong Kong; Hong Kong China

3. State Key Laboratory of Digestive Disease; The Chinese University of Hong Kong; Hong Kong China

4. Department of Statistics; The Chinese University of Hong Kong; Hong Kong China

5. Big Data Decision Analytics Research Centre; The Chinese University of Hong Kong; Hong Kong China

Funder

Chinese University of Hong Kong

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14015/fullpdf

Reference39 articles.

1. Hepatitis B virus infection;Trepo;Lancet,2014

2. Hepatitis B therapy;Kwon;Nat Rev Gastroenterol Hepatol,2011

3. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis;Wong;Hepatology,2013

4. Current developments in nucleoside/nucleotide analogues for hepatitis B;Lo;Expert Rev Gastroenterol Hepatol,2014

5. EASL clinical practice guidelines: management of chronic hepatitis B virus infection;European association for the study of the liver;J Hepatol,2012

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study;Clinical and Molecular Hepatology;2024-07-01

2. Entecavir versus tenofovir on prognosis of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy;Alimentary Pharmacology & Therapeutics;2023-03-13

3. Population-Based Clinical Studies Using Routinely Collected Data in Hong Kong, China: A Systematic Review of Trends and Established Local Practices;Cardiovascular Innovations and Applications;2023

4. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B;Journal of Hepatology;2022-12

5. Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis;Beni-Suef University Journal of Basic and Applied Sciences;2022-09-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3